Chorea associated with Huntington's disease: To treat or not to treat?

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1414-1418

  Jankovic, Joseph ^a   Roos, Raymund A C ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOREA; COMPLICATION; HUMAN; HUNTINGTON DISEASE;

CHOREA; HUMANS; HUNTINGTON DISEASE;

EID: 84907931765     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25996     Document Type: Article

References (37)

1. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014 [Epub ahead of print].
2. Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry 1999;66:52-56.
3. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8:844-856.
4. Fekete R, Jankovic J. Upper face chorea in Huntington disease. J Clin Mov Disord 2014 (in press).
5. Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012;27:935-946.
6. Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm 2013;120:1579-1589.
7. Fahn S, Jankovic J, Hallett M. Principles and Practice of Movement Disorders, Churchill Livingstone, Elsevier, Philadelphia, PA, 2011, p. 6.
8. Snowden JS1, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998;55:801-805.
9. Sitek EJ1, Soldtan W, Wieczorek D, et al. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. J Int Neuropsychol Soc 2011;17:788-795.
10. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
11. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
12. Justo D, Charles P, Daunizeau J, et al. Is non-recognition of choreic movements in Huntington disease always pathological? Neuropsychologia 2013;51:748-759.
13. Jankovic J, Fahn S. Choreas. In: Rowland LP, Pedley T, eds. Merritt's Textbook of Neurology. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, 2010:727-731.
14. Paulsen JS, Wang C, Duff K, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord 2010;25:2595-2603.
15. Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Development of the Huntington disease work function scale. J Occup Environ Med 2012;54:1300-1308.
16. Sánchez-Pernaute R, Künig G, del Barrio Albe A, et al: Bradykinesia in early Huntington's disease. Neurology 2000;54:119-125.
17. Fenney A, Jog MS, Duval C. Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology. Brain Res 2008;1193:67-75.
18. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 2008;23:1100-1107.
19. Biglan KM, Ross CA, Langbehn DR, et al. Motor abnormalities in premanifest persons with Huntington's disease: the REDICT-HD study. Mov Disord 2009;24:1763-1772.
20. Reedeker N, Van Der Mast RC, Giltay EJ, et al. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning. Mov Disord 2010;25:1612-1618.
21. Dorsey ER, Beck CA, Darwin K, et al. Natural history of Huntington disease. JAMA Neurol 2013;70:1520-1530.
22. Bohlen S, Ekwall C, Hellström K, Vesterlin H, Björnefur M, Wiklund L, Reilmann R. Physical therapy in Huntington's disease: toward objective assessments? Eur J Neurol 2013;20:389-393.
23. Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease: toward objective and quantitative measures. Mov Disord 2011;26:2267-2273.
24. Rao AK, Gordon AM, Marder KS. Coordination of fingertip forces during precision grip in premanifest Huntington's disease. Mov Disord 2011;26:862-869.
25. Devos H, Nieuwboer A, Tant M, et al. Determinants of fitness to drive in Huntington disease. Neurology 2012;79:1975-1982.
26. Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord 2014;29:285-293.
27. Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010;70:561-571.
28. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603.
29. Reilmann R. Pharmacological treatment of chorea in Huntington's disease: good clinical practice versus evidence-based guideline. Mov Disord 2013;28:1030-1033.
30. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Exp Rev Neurother 2011;11:1509-1523.
31. Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease. Exp Opin Orphan Drugs 2013;1:423-436.
32. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term treatment of chorea associated with Huntington's and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013 Oct 22;3. pii: tre-03-191-4337-1. eCollection 2013.
33. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
34. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013;28:210-215.
35. Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. Version 2. PLoS Curr 2011 [revised 2011 Oct 11];3:RRN1260.
36. Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in Huntington disease: a pilot open label study. Tremor Other Hyperkinet Mov (NY), 2012;2.
37. Ferrara JM, Mostile G, Hunter C, Adam OR, Jankovic J. Effect of tetrabenazine on motor function in patients with Huntington disease. Neurol Ther 2012;1:5.